Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol’s Termination Of Dolan Follows Federal Monitor’s Recommendation

This article was originally published in The Pink Sheet Daily

Executive Summary

However, the company’s monitor and the U.S. Attorney for New Jersey conclude that Bristol has not violated a deferred prosecution agreement.

Related Content

Bristol Pleads Guilty To Criminal Charges To Settle DoJ Investigation Over Plavix
Bristol/Sanofi Receive FTC Subpoena Over Failed Plavix Settlement With Apotex
Sanofi/Bristol Plavix Patent Suit To Begin Against Apotex
Bristol Reaches Tentative Settlement With U.S. Attorney
Billionaire Icahn Named ImClone Chairman, Interim CEO Resigns
PhRMA’s Unlucky Class Of ‘06
PhRMA’s Unlucky Class Of ‘06
Bristol Lowers EPS Guidance On Plavix Decision
Bristol/Sanofi's Plavix Settlement Faces Justice Department Criminal Investigation
Bristol Settles DoJ "Channel Stuffing" Investigation For $300 Mil.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts